Seven plus eight makes six for Globus
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
Does Novartis really love lentiviral?
The company is rumoured to be pursuing Avrobio, which would be a bargain even by gene therapy standards.
The world's twelfth VEGF drug will be sold by Takeda
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.
